Results of the phase 3 KEYNOTE-564 study demonstrated the efficacy of adjuvant pembrolizumab for patients with clear cell renal cell carcinoma (ccRCC) and increased risk of recurrence after nephrectomy by prolonging disease-free survival (DFS) compared with placebo. At the 24th Annual Meeting of the Society of Urologic Oncology, Dr. Tian Zhang, of UT Southwestern Medical Center, presented the results of a post hoc exploratory analysis on DFS in patient subgroups from the trial, based on the UCLA Integrated Staging System (UISS) risk groups and disease stage. ...
Advanced Renal Cell Carcinoma
Advertisement
Latest News
An analysis compared the outcomes of patients with mRCC who underwent cytoreductive nephrectomy and first-line TKI or IO.
TKI monotherapy and TKI plus non-IO therapy was the most common subsequent treatment utilized after receiving IO-TKI.
Researchers evaluated survival outcomes, demographic data, and clinical presentation.
Past 12 months, the effectiveness and safety between nivolumab plus ipilimumab and pembrolizumab plus axitinib were similar.
Researchers compared the efficacy benefits of nivolumab plus cabozantinib with sunitinib alone.
The TRAE rates of 1L nivolumab plus ipilimumab were low and remained consistent relative to clinical trials.
Advertisement
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Drs. Wallis and Sartor highlight issues with the control arm and considerations for treatment sequencing related to PSMAfore.
Dr. Sartor explains in detail the design and methodology, specific findings, nuances, and implications of the PSMAfore trial.
Drs. Joyce and Wallis consider the impact of financial toxicity and containing costs for patients with GU malignancies.
Drs. Pal and Wallis break down the role of the microbiome and response in patients with kidney cancer.
Dr. Prasad presented the results of the ENVISION trial assessing primary chemoablation in patients with LG-IR NMIBC.
Researchers sought to identify the frequency of germline mutations in patients 46 years or younger.
Advertisement
Advertisement
Trending
The first PET scans using Illuccix, Telix’s PSMA-PET imaging agent, have been carried out in cooperation with BAMF Health.
Nanobubbles can target membrane proteins, including PSMA, to bind to receptors that are overexpressed in cancer cells.
Few biomarkers predict therapeutic response to radiation or adjunctive treatments in PCa patients treated with radiotherapy.
